EUDA EUDA HEALTH HLDGS LTD

EUDA Health Holdings Limited Has Regained Compliance with Nasdaq Capital Market’s Continued Listing Requirements

EUDA Health Holdings Limited Has Regained Compliance with Nasdaq Capital Market’s Continued Listing Requirements

Singapore, Sept. 22, 2023 (GLOBE NEWSWIRE) -- As previously disclosed, EUDA Health Holdings Limited (“EUDA” and the “Company”) received a written notice from Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) on August 10, 2023 indicating that the Company was not in compliance with the $1.00 Minimum Bid Price requirement set forth in the Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market (the “Bid Price Requirement”). On September 14, 2023, the Company received a written notice from Nasdaq stating that the closing bid price of the Company’s common stock has been at $1.00 per share or greater for 10 consecutive business days from August 30 to September 13, 2023, and therefore the Company has regained compliance with the $1.00 Minimum Bid Price Requirement for continued listing on The Nasdaq Capital Market.

As previously disclosed, the Company received a written notice from Nasdaq on July 31, 2023 indicating that the Company had failed to maintain a minimum market value of listed securities of $35 million over the previous 30 consecutive business days (the “MVLS Requirement”) as required by the Nasdaq Listing Rule 5550(b)(2). On September 20, 2023, the Company received a written notice from Nasdaq stating that the Company’s market value of listed securities has been $35 million or greater for 10 consecutive business days from September 6 to September 19, 2023, and therefore the Company has regained compliance with the MVLS Requirement for continued listing on The Nasdaq Capital Market.

All matters relating to the Company’s previous non-compliance with the Nasdaq Capital Market’s continued listing rules are now closed.

For investor and media inquiries, please contact:

Dr. Kelvin Chen

Chief Executive Officer

EUDA Health Holdings Limited





EN
22/09/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on EUDA HEALTH HLDGS LTD

 PRESS RELEASE

EUDA Signs Letter of Intent to Potentially Acquire GO POSB

EUDA Signs Letter of Intent to Potentially Acquire GO POSB SINGAPORE, Sept. 10, 2025 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) (“EUDA” or the “Company”), a Singapore-based non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, today announced that its wholly-owned subsidiary, EUDA Health Pte. Ltd. (“EUDA Health”), has signed a Letter of Intent (the “LOI”) to potentially acquire GO POSB Organoids Pte Ltd (“GO POSB”), a biotechnology company formed in Singapore. GO POSB has developed a proprietary induced pluripotent stem cell (iPSC) pla...

 PRESS RELEASE

EUDA Strategically Expands into T-Cell Immunotherapy – Strengthening I...

EUDA Strategically Expands into T-Cell Immunotherapy – Strengthening Its Stem Cell Therapy Portfolio SINGAPORE, Sept. 04, 2025 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (“EUDA” or the “Company”) (NASDAQ: EUDA), a leading Singapore-based non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia, and China, today announced that it has secured distribution rights for T-cell immunotherapies in Malaysia developed by Shenzhen Inno Immune Co. Ltd. (“Shenzhen Inno”), a developer of autologous cellular therapeutic and customized medicines for a wide range of diseases in ...

 PRESS RELEASE

EUDA Signs Letter of Intent to Potentially Acquire Chemokine Pte Ltd

EUDA Signs Letter of Intent to Potentially Acquire Chemokine Pte Ltd SINGAPORE, Aug. 28, 2025 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) (“EUDA” or the “Company”), a leading Singapore-based non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, today announced that it has signed a Letter of Intent (the “LOI”) to potentially acquire Chemokine Pte Ltd (“Chemokine”). EUDA will carry out due diligence on Chemokine, subject to confidentiality obligations. Chemokine has agreed to an exclusivity period of at least one hundred and twenty (120) d...

 PRESS RELEASE

EUDA Expands Wellness Product Portfolio With A Next-Generation Immune ...

EUDA Expands Wellness Product Portfolio With A Next-Generation Immune Health Supplement SINGAPORE, Aug. 26, 2025 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) (“EUDA” or the “Company”), a leading Singapore-based non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, today announced that its wholly-owned subsidiary, EUDA Health Pte. Ltd., has secured exclusive worldwide distribution rights for a next-generation immune health supplement (the “Supplement”) from Chemokine Pte. Ltd. (“Chemokine”), a Singapore-based biotech company focused on mole...

 PRESS RELEASE

EUDA Partners with Authorized Distributor of Guangdong Cell Biotech to...

EUDA Partners with Authorized Distributor of Guangdong Cell Biotech to Offer Stem Cell Therapies to Customers in Singapore and Malaysia SINGAPORE, April 24, 2025 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (“EUDA” or the “Company”) (NASDAQ: EUDA), a Singapore-based property management services provider and a leading non-invasive healthcare provider in Singapore and Malaysia, today announced an update to the potential strategic partnership, previously announced in December 2024, with Guangdong Cell Biotech Co. Ltd. (“Guangdong Cell Biotech”). Guangdong Cell Biotech is a prominent pla...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch